Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer †

Overview of attention for article published in Annals of Oncology, March 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 1 news outlet
policy: 2 policy sources

twitter: 21 X users
reddit: 1 Redditor

Readers on

mendeley: 76 Mendeley

So far, Altmetric has seen 22 X posts from 21 X users, with an upper bound of 153,425 followers.

RT @Annals_Oncology: Progression-free survival in clinical trials of HER2-targeted agents in metastatic #breastcancer https://t.co/HQIRbqKa…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 18 additional X posts.